Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.

Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Two new studies that have been published recently show that people who have been taking weight loss drugs may have encountered an increased risk of serious eye conditions and vision loss.